Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Sep;50(3):221-6.
doi: 10.1111/j.1365-2125.2000.00246.x.

Heparin-mediated selective release of hepatocyte growth factor in humans

Affiliations
Clinical Trial

Heparin-mediated selective release of hepatocyte growth factor in humans

P B Salbach et al. Br J Clin Pharmacol. 2000 Sep.

Abstract

Aims: The aim of this investigation was to compare the effects of standard (S) with low molecular weight (LMW) heparin on circulating levels of heparin-binding growth factors (HBGF), known to have angiogenic properties in humans.

Methods: In two consecutive trials 18 healthy male volunteers were studied on three separate occasions, following a placebo-controlled crossover design. Subjects were randomised to receive either S-heparin or LMW heparin or placebo. Heparins were administered either by intravenous (i.v.) or subcutaneous (s.c.) injection and saline placebo by i.v. injection. Serum concentrations of hepatocyte growth factor (HGF), vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were measured before and up to 24 h after injection.

Results: Administration of i.v. S-or LMW-heparin (50 IU kg(-1) resulted in rapid, highly significant (47 fold for S, 30.9 fold for LMW) increases in HGF serum values, reaching maxima of 10.51+/-1.65 ng ml(-1) (S) and 8.28+/-1.04 ng ml(-1) (LMW), respectively, 10 min after drug application. S.c. injection of S-heparin or LMW heparin resulted in 4.1 and 5.4 fold increases in HGF serum values, respectively. Both agents showed no effects on circulating VEGF or bFGF levels, independent of the route of administration.

Conclusions: Circulating HGF levels were selectively increased in response to pharmacological doses of two, widely used heparin preparations. This may, in part, explain some of the biological effects of heparin separate from its anticoagulant properties. By this mechanism, the systemic administration of heparin may facilitate collateral vessel formation in various clinical settings of tissue ischaemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Profiles of the mean serum concentration over time for circulating HGF in human subjects following a single dose of either 50 IU kg−1 body weight S-heparin (a) administered i.v. (□), s.c. (▵) or placebo i.v. (•), or (b) LMW-heparin administered either i.v. (▪) or s.c. (▴) or placebo i.v. (○). Results are expressed as mean ± 1 s.d.

Similar articles

Cited by

References

    1. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443. - PubMed
    1. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Comm. 1997;239:639–644. - PubMed
    1. Grant SD, Kleinmann HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci. 1993;90:1937–1941. - PMC - PubMed
    1. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte Growth factor is a potent angiogenic factor which stimulates endothelial cell mobility and growth. J Cell Biol. 1992;119:629–641. - PMC - PubMed
    1. van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation. 1998;97:381–390. - PubMed

Publication types

MeSH terms